n=48

Patients from Personalised Anti-TNF Therapy in CD study (PANTs)

n=278

Patients in   
initial treatment analysis

n=230

Patients with complete audit data (demographic, disease, and initial treatment data)

n=175

Remicade patients:

CD (n=129)  
UC (n=32)

IBDU (n=14)

n=82

Inflectra/Remsima Patients:

CD (n=63)

UC (n=14)

IBDU (n=5)

n=21

Adalimumab Patients:

CD (n=19)

UC (n=1)

IBDU (n=1)

**Supplementary figure 1. Patient flow chart**

CD = Crohn’s disease; UC = ulcerative colitis; IBDU = inflammatory bowel disease unclassified.